Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.

Laura Fernandez-Rodriguez,Chiara Cianciaruso,Ruben Bill,Marcel P Trefny,Richard Klar,Nicole Kirchhammer,Mélanie Buchi,Julia Festag,Sven Michel,Rainer H Kohler,Elham Jones,Andre Maaske,Abhishek S Kashyap,Frank Jaschinski,Karen O Dixon,Mikael J Pittet,Alfred Zippelius

Journal for immunotherapy of cancer（2023）

Cited 0|Views14
No score
Abstract
By simultaneously targeting TLR9 and PD-L1, IM-T9P1-ASO amplifies antitumor responses via DC activation, leading to sustained therapeutic efficacy in mice. By highlighting differences and similarities between mouse and human DCs, this study could serve to develop similar therapeutic strategies for patients with cancer.
More
Translated text
Key words
immunotherapy, immune checkpoint inhibitors, combined modality therapy, dendritic cells
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined